

# Folker Westphal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7397366/publications.pdf>

Version: 2024-02-01

14  
papers

321  
citations

1162367

8  
h-index

1058022

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Separating the wheat from the chaff: Observations on the analysis of lysergamides LSD, MIPLA, and LAMPA. <i>Drug Testing and Analysis</i> , 2022, 14, 545-556.	1.6	8
2	Return of the lysergamides. Part VII: Analytical and behavioural characterization of 1- <i>valeroyl</i> -lysergic acid diethylamide (1V-LSD). <i>Drug Testing and Analysis</i> , 2022, 14, 733-740. <sup>1.6</sup>	1.6	8
3	Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-LAD. <i>Drug Testing and Analysis</i> , 2022, 14, 1503-1518.	1.6	7
4	Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233. <i>Drug Testing and Analysis</i> , 2021, 13, 175-196.	1.6	9
5	Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ). <i>Drug Testing and Analysis</i> , 2020, 12, 1514-1521.	1.6	4
6	Syntheses and analytical characterizations of novel (2-aminopropyl)benzo[ b ]thiophene (APBT) based stimulants. <i>Drug Testing and Analysis</i> , 2020, 12, 1109-1125.	1.6	2
7	Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-lysergic acid diethylamide (1CP-LSD). <i>Drug Testing and Analysis</i> , 2020, 12, 812-826.	1.6	17
8	Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-lysergic acid diethylamide (1B-LSD). <i>Drug Testing and Analysis</i> , 2019, 11, 1122-1133.	1.6	43
9	Syntheses and analytical characterizations of the research chemical 1-(2-(2-fluorophenyl)-2-phenylethyl)pyrrolidine (fluorolintane) and five of its isomers. <i>Drug Testing and Analysis</i> , 2019, 11, 1144-1161.	1.6	6
10	Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). <i>Drug Testing and Analysis</i> , 2018, 10, 310-322.	1.6	40
11	Return of the lysergamides. Part II: Analytical and behavioural characterization of N <sup>6</sup> -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2 <sup>TM</sup> -S</i>, 4 <sup>TM</sup> -S</i>)lysergic acid 2,4-dimethylazetidide (LSZ). <i>Drug Testing and Analysis</i> , 2017, 9, 38-50.	1.6	51
12	Return of the lysergamides. Part III: Analytical characterization of N <sup>6</sup> -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). <i>Drug Testing and Analysis</i> , 2017, 9, 1641-1649.	1.6	33
13	Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-lysergic acid diethylamide (1P-LSD). <i>Drug Testing and Analysis</i> , 2016, 8, 891-902.	1.6	64
14	Ring positional differentiation of isomeric N-alkylated fluorocathinones by gas chromatography/tandem mass spectrometry. <i>Forensic Science International</i> , 2012, 223, 97-105.	1.3	29